Competitor's Record-Price Drug Could Add To Biogen's Challenges
The FDA this month is expected to approve a new therapy that will compete with Spinraza, which generated $1.7 billion for Cambridge-based Biogen last year. |!| Cambridge Boston
More from Greater Boston
CBS Local Boston Sports
Turgeman scores 2 goals, Revolution beat Cincinnati 3-2, clinch playoff berth
Greater Boston
•
6h ago
The Harvord Crimson | Sports
Harvard Men's Water Polo Closes First Round of Conference Play With Four Straight Wins
Greater Boston
•
8h ago
The Harvard Crimson | News
Weeks After School Starts, Staffing Shortages Leave More Than 20 Children Without Afterschool Care
Greater Boston
•
8h ago
The Boston Hockey Blog
BU downs Vermont 2-1 in overtime thanks to two Ryder Ritchie goals
Greater Boston
•
12h ago
WHDH 7 Boston
Best Buddies Friendship Walk supports those with intellectual and developmental disabilities
Greater Boston
•
13h ago
The Boston Hockey Blog
Takeaways: A slow first period plagues BU in 1-0 loss against Colgate
Greater Boston
•
14h ago
The Boston Pilot
As pope faces cancer, biographers say it's too early to predict changes to his papacy
Greater Boston
•
15h ago